Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2017-03-30 Earnings Release
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
2017年度第一季度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a quarterly earnings forecast for the first quarter of 2017, covering the period from January 1 to March 31, 2017. It provides estimated financial results (net profit growth percentages and amounts) but explicitly states that the figures are unaudited and preliminary. The document is short (654 characters) and serves as an earnings preview rather than a full financial report. It does not contain actual financial statements or detailed analysis, only a forecast and explanation of expected performance changes. Therefore, it fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only. Q1 2017
2017-03-30 Chinese
独立董事2016年度述职报告（于建青）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2016 Annual Work Report" for a company, detailing the independent director's activities, attendance at board meetings, opinions expressed, committee roles, and efforts to protect investor rights during the 2016 fiscal year. It is a narrative report on the director's duties and oversight rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it an announcement of voting results or management changes. This type of document fits best under Board/Management Information (MANG), as it relates to the activities and reports of a board member.
2017-03-30 Chinese
2016年年度报告
Annual Report Classification · 100% confidence The document is titled "瑞康医药股份有限公司 2016 年年度报告全文" which translates to "Realcan Pharmaceutical Co., Ltd. 2016 Annual Report Full Text." It contains detailed financial data for the fiscal year 2016, including revenue, net profit, segment analysis, business overview, management discussion and analysis, and other comprehensive information typical of an annual report. The document length is 15,000 characters, indicating a full report rather than a brief announcement. It includes sections such as company overview, financial highlights, business segments, and detailed financial statements. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2016
2017-03-30 Chinese
关于为全资子公司申请银行综合授信提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 瑞康医药股份有限公司 regarding providing a guarantee for its wholly-owned subsidiary's application for a bank comprehensive credit facility. It details the guarantee amount, terms, the subsidiary's financial status, board approval, and independent director opinions. The document is a formal announcement of a financing-related guarantee and does not contain financial statements or detailed financial reports. It is not a full financial report, audit report, or earnings release. The content fits the category of Capital/Financing Update (CAP), as it relates to financing activities and guarantees provided by the company.
2017-03-30 Chinese
2016年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2016 年年度报告摘要" which translates to "2016 Annual Report Summary". It contains detailed financial data for the year 2016, including revenue, net profit, business segments, and shareholder information. The text references the full annual report and emphasizes that this is a summary derived from the full annual report. The length of the document (8511 characters) and the presence of comprehensive financial and operational data indicate this is a substantive financial report rather than a brief announcement or a certification. The content aligns with the characteristics of an Annual Report (10-K) as it covers company activity, financial performance, and business overview for the fiscal year. Therefore, the appropriate classification is Annual Report (10-K). FY 2016
2017-03-30 Chinese
独立董事关于对公司累计和当期担保情况的专项说明及独立意见
Regulatory Filings Classification · 95% confidence The document is a special statement and independent opinion by the independent directors of 瑞康医药股份有限公司 regarding the company's cumulative and current guarantee situation. It references regulatory guidance from the China Securities Regulatory Commission (证监发[2005]120号) about external guarantees by listed companies. The content is a formal attestation and opinion on compliance and risk control related to guarantees, signed by independent directors. It does not contain financial statements or detailed financial data, nor is it a full audit report or annual report. It is primarily a certification or attestation document by officers (independent directors). According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS). The document length is short (677 characters), and it is not an announcement of a report but the attestation itself. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2017-03-30 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.